HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analgesic Links To Renal Failure, Interactions Studied In NEJM

This article was originally published in The Tan Sheet

Executive Summary

Acetaminophen dosing in excess of 500 g per year among regular users of the analgesic increases the risk of chronic renal failure by 530%, a study in the Dec. 20 New England Journal of Medicine reports

You may also be interested in...



Acetaminophen GI Label Warnings Justified By Recent Data, Bayer Contends

Acetaminophen products should be required to carry gastrointestinal warnings similar to those on aspirin labeling, Bayer Consumer Care asserts

Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court

A recent British Medical Journal study does not support McNeil Consumer & Specialty Pharmaceuticals' advertising claims that 81 mg aspirin "is just as effective as 325 mg in reducing the risk of recurrent heart attacks," Bayer says in a lawsuit filed in New York federal court April 25

Pediatric Acetaminophen Toxicity Literature Distribution Supported By AAP

Written information about acetaminophen toxicity should be given to parents at their children's regular medical check-ups and discussed at later visits, the American Association of Pediatrics' Committee on Drugs advises in a policy statement in the October issue of Pediatrics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel